PMID- 38414708
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240229
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 16
IP  - 1
DP  - 2024 Jan
TI  - Dupilumab-Related Diabetes Mellitus With Reversal of Symptoms in a 
      Non-genetically Predisposed Patient.
PG  - e53080
LID - 10.7759/cureus.53080 [doi]
LID - e53080
AB  - Dupilumab is a fully humanized monoclonal antibody that binds to IL-4 receptors 
      and blocks IL-4 and IL-13 mediated T-helper 2 (Th2) responses. Dupilumab is 
      estimated to be used by over 600,000 patients worldwide for the treatment of 
      atopic dermatitis and other immunologic conditions. Recently, a 66-year-old male 
      patient being treated for atopic dermatitis with dupilumab presented to the 
      clinic with complaints of polyuria and polydipsia. Upon initial testing, the 
      patient was found to have considerable hyperglycemia. Upon genetic testing, he 
      showed no predisposition for autoimmune diabetes and was negative for type I 
      diabetes mellitus-associated human leukocyte antigen (HLA) genes. After immediate 
      cessation of dupilumab, and with subsequent insulin therapy, the patient was able 
      to obtain glycemic control. Following taper and eventual cessation of insulin 
      therapy and over the course of seven months, the patient was able to achieve a 
      full resolution of symptoms and his glycosylated hemoglobin (HgBA1c) levels 
      returned to normal ranges. This case represents only the second documented case 
      of dupilumab-induced diabetes mellitus and is the first known documented case of 
      dupilumab-induced diabetes mellitus in a non-genetically predisposed individual. 
      This case also describes a previously unobserved spontaneous resolution of 
      symptoms upon cessation of the drug. This case further illustrates the potential 
      existence of immunogenic or immunomodulatory side effects of the monoclonal 
      antibody dupilumab that can affect patients who are both genetically and 
      non-genetically predisposed to autoimmune diabetes mellitus.
CI  - Copyright (c) 2024, Blaylock et al.
FAU - Blaylock, Tanner C
AU  - Blaylock TC
AD  - College of Allopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel 
      College of Allopathic Medicine, Fort Lauderdale, USA.
FAU - Leon, Daniel
AU  - Leon D
AD  - College of Allopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel 
      College of Allopathic Medicine, Fort Lauderdale, USA.
AD  - Internal Medicine, Chen Senior Medical Center, Plantation, USA.
LA  - eng
PT  - Case Reports
DEP - 20240127
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10897062
OTO - NOTNLM
OT  - autoimmune disease
OT  - autoimmune type 1 diabetes mellitus
OT  - dupilumab
OT  - immunogenicity
OT  - monoclonal antibodies (mabs)
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/02/28 06:44
MHDA- 2024/02/28 06:45
PMCR- 2024/01/27
CRDT- 2024/02/28 03:49
PHST- 2023/12/15 00:00 [received]
PHST- 2024/01/26 00:00 [accepted]
PHST- 2024/02/28 06:45 [medline]
PHST- 2024/02/28 06:44 [pubmed]
PHST- 2024/02/28 03:49 [entrez]
PHST- 2024/01/27 00:00 [pmc-release]
AID - 10.7759/cureus.53080 [doi]
PST - epublish
SO  - Cureus. 2024 Jan 27;16(1):e53080. doi: 10.7759/cureus.53080. eCollection 2024 
      Jan.